



Growth Factors and Neuroglobin in Astrocyte Protection Against Neurodegeneration and Oxidative Stress

Ricardo Cabezas^{1,2} · Eliana Baez-Jurado¹ · Oscar Hidalgo-Lanusca¹ · Valentina Echeverría^{3,4} · Ghulam Md Ashrad⁵ · Amirhossein Sahebkar^{6,7,8} · George E. Barreto^{1,9} 

Received: 10 April 2018 / Accepted: 26 June 2018 / Published online: 7 July 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Abstract

Neurodegenerative diseases, such as Parkinson and Alzheimer, are among the main public health issues in the world due to their effects on life quality and high mortality rates. Although neuronal death is the main cause of disruption in the central nervous system (CNS) elicited by these pathologies, other cells such as astrocytes are also affected. There is no treatment for preventing the cellular death during neurodegenerative processes, and current drug therapy is focused on decreasing the associated motor symptoms. For these reasons, it has been necessary to seek new therapeutical procedures, including the use of growth factors to reduce α -synuclein toxicity and misfolding in order to recover neuronal cells and astrocytes. Additionally, it has been shown that some growth factors are able to reduce the overproduction of reactive oxygen species (ROS), which are associated with neuronal death through activation of antioxidative enzymes such as catalase, superoxide dismutase, glutathione peroxidase, and neuroglobin. In the present review, we discuss the use of growth factors such as PDGF-BB, VEGF, BDNF, and the antioxidative enzyme neuroglobin in the protection of astrocytes and neurons during the development of neurodegenerative diseases.

Keywords PDGF-BB · Neuroglobin · Astrocyte · Oxidative stress · Neurodegeneration

✉ George E. Barreto
gsampaio@javeriana.edu.co; gesbarreto@gmail.com

¹ Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia

² Departamento de Ciencias Básicas, Universidad Santo Tomás, Bucaramanga, Colombia

³ Facultad de Ciencias de la Salud, Universidad San Sebastián, Lientur 1457, 4030000 Concepción, Chile

⁴ Research and Development, Bay Pines VA Healthcare System, Bay Pines, FL 33744, USA

⁵ King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia

⁶ Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

⁷ Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

⁸ School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

⁹ Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile

Introduction

Neurodegenerative diseases are among the main public health problems in the world. It has been estimated that by the year 2020, there will be around 40 million people affected in the world by pathologies such as Alzheimer's disease (AD), Parkinson's disease (PD), epilepsy, multiple sclerosis, and cerebrovascular accidents. Likewise, it is expected that by 2030, mortality from neurodegenerative diseases will reach 12.22% of global population [1].

PD manifests with a heterogeneity of symptoms such as resting tremor, bradykinesia, muscle hypertonia, postural instability, and cognitive and language alterations, which seriously affect the quality of life in patients [2, 3]. These symptoms are due to the selective degeneration of dopaminergic neurons (DA) of the substantia nigra pars compacta (Fig. 1), which results in an exacerbated decrease in dopamine levels [4–6].

The current pharmacological treatments for PD such as levodopa, carbidopa, dopamine receptor agonists, COMT (catechol-O-methyltransferase), or MAO-B (monoamine oxidase) inhibitors and deep brain stimulation are symptomatic and mainly focus on maintaining or prolonging the daily




Fig. 1 Mitochondrial effects in PD. Alterations in mitochondrial proteins (parkin (PARK2) or PINK1) due to mutations or environmental effects may induce mitochondrial damage and increase ROS, along with drop in

membrane potential mitochondrial ($\Delta\Psi_m$), formation of α -synuclein aggregates, and activation of apoptotic mechanisms in DAs are considered as hallmarks during PD onset

activities of patients, without interfering with the progression of the disease [7–9]. Likewise, these pharmacological treatments lead to motor complications in 50–90% of cases together with a loss in their effectiveness after 2 to 5 years [8]. For this reason, it has been necessary to seek new treatments and methodologies for this pathology including the use of simvastatin and other non-steroidal agents, overexpression of chaperone proteins such as GRP78 to reduce misfolding and α -synuclein toxicity, transplantation of mesenchymal stem cells, spinal cord electric stimulation, and the use of growth factors [10–13].

Different growth factors such as fibroblast growth factor (FGF), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), and platelet-derived growth factor (PDGF) have been used in various models of neuroprotection including cell lines, animal models, and clinical trials. It has been observed that these growth factors protect neurons and glial cells against excitotoxic and oxidative insults through the production of antioxidant enzymes, chaperones, activation of cellular survival pathways, and mitochondrial protection [13–18]. Unfortunately, growth factors such as BDNF and NGF, when used in human clinical trials, showed harmful side effects including nausea and extreme pain [19].

In the case of PDGF, it has been shown that some isoforms have neuroprotective effects against ischemic damage in rat pyramidal neurons, N-methyl-D-aspartate (NMDA) insult in retina of murine models, 6-OHDA in neurons, and TAT toxin of HIV [18, 20–22]. Similarly, recent clinical trials have reported that intracerebroventricular infusion of different doses of platelet-derived growth factor, isotype BB (PDGF-BB) produced no adverse effects in patients [13]. These results suggest that PDGF-BB has promising protective effects in the treatment of neurodegenerative diseases including PD.

Although dopaminergic neurons are the main cells affected in PD, numerous studies have demonstrated the participation of glial cells (microglia, astrocytes, and oligodendroglia) in the development of inflammatory events and degenerative processes that are present in PD [23–26]. These include augmented astrocytic reactivity in post-mortem brains of patients with PD, increased release of interferon- γ and neurotrophic factors, high levels of glutathione peroxidase (GPx), and increases in the endocytosis of α -synuclein by astrocytes [27]. Taking into account the abovementioned findings, this review highlights the need for novel neuronal and astrocytic protection strategies. We also sought to provide evidence on the efficacy of new protective molecules such as neuroglobin (ngb1), PDGF-BB, and other growth factors and to introduce

novel therapeutic strategies aimed at reducing mitochondrial oxidative damage in PD.

Mitochondria and Neurodegeneration

Mitochondria are critical organelles for cell survival and normal development, since these organelles are the main modulators of cellular energy through the electron transport chain and ATP synthesis. They are also the main regulators of apoptotic death and aging and are involved in the control of calcium homeostasis and ROS production [28–31]. Various neurodegenerative diseases, such as AD, stroke, Huntington's disease (HD), and PD, are associated with mitochondrial dysfunction, increased ROS production, and activation of apoptosis [31].

Currently, it is thought that the development of PD is either genetic or idiopathic. For example, several genes involved in its etiopathogenesis have been identified, and these include *PARK8*, *PARK2*, *PARK7* (DJ-1), *PINK1*, and *SNCA*, which encode for parkin and α -synuclein that accumulate in Lewy plaques or bodies in dopaminergic neurons [1, 5]. Some of these proteins, LRRK2, PINK1, and PARK7, are also involved in the regulation of mitochondrial functions (Fig. 1) like the maintenance of mitochondrial membrane potential ($\Delta\Psi_m$) and the production of reactive oxygen species (ROS) and are thus affected during PD development [32, 33]. Likewise, it has been suggested that the response to unfolded proteins (UPR) is also involved in the development of PD [34–36]. In this case, increased ROS (reactive oxygen species) levels and imbalance in calcium levels that occur during the PD onset lead to an increase in the accumulation of misfolded proteins, including α -synuclein, which in turn induces the activation of regulatory proteins of the UPR such as PERK kinase, inositol 1 α -dependent enzyme (Ire1 α), transcription factor 6 α (ATF6 α), and the chaperone GRP78/Bip [34–37].

Various studies have shown that the production and accumulation of cytotoxic factors produce degenerative alterations in neurons [38–41]. Neurotoxicity has been attributed to high levels of ROS, nitric oxide, interleukin-1 β (IL-1 β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF- α), which can affect mitochondrial energetic processes in dopaminergic neurons and as consequence the activation of apoptotic pathways (Fig. 1) through a mechanism dependent on cytochrome c and caspase 3 [40]. Similarly, environmental and occupational factors have been shown to explain the rise in PD prevalence. Some of which include exposure to pesticides and herbicides (including rotenone and paraquat) by agricultural workers, and other factors include genetic environmental interactions, dietary factors such as consumption of polyunsaturated fatty acid, UPR, or the composition of the intestinal microbiome [36, 39, 42]. For these reasons,

maintenance of mitochondrial properties in neurons and astrocytes are of main importance during brain injury and neurodegeneration (Barreto et al. 2011).

Astrocytic Functions: Interactions Between Neurons and Astrocytes in PD

Astrocytes are the most common type of cells in the brain of mammals and make up the glia along with oligodendrocytes and microglial cells [43]. These cells are organized in a syncytial network and are strongly communicated with each other and, in turn, with other cells such as pericytes, endothelial cells, and neurons [44]. Astrocytes (Fig. 2) are fundamental for processes such as the development and/or maintenance of the blood-brain barrier, promotion of neurovascular coupling, recruitment of cells through the release of chemokines, release of gliotransmitters, regulation of calcium levels, release and transport of glutamate by calcium signaling through the glutamate aspartate transporter (GLAST) and excitatory amino acid transporter (EAAT), maintenance of the general metabolism of the brain, control of cerebral pH, uptake of GABA (γ -aminobutyric acid) by specific transporters, and production of antioxidant enzymes [45–48]. During brain damage (e.g., oxidative stress), these processes are temporarily or permanently affected and the consequent impact on neuronal cells can lead to pathological conditions and neurodegenerative diseases [45, 46]. In this regard, it is important to note that neurons are more susceptible to injury than astrocytes since they have a lower antioxidant capacity and require a greater deal of metabolic coupling with astrocytes to combat oxidative stress [45]. Both under normal circumstances and after brain injury, astrocytes provide neurons with antioxidant protection, neurotrophic factors, substrates for neuronal metabolism, and glutamate reuptake [28, 49]. Although astrocytes are generally more resistant than neurons during traumatic or degenerative insult, these cells can also suffer severe damage which will result in increased neuronal death [49].

Astrocytes respond to most types of brain insults (infections, traumas, ischemia, oxidative stress, and neurodegenerative stimuli) by a process called reactive astrogliosis [50–52]. This process involves both morphological and molecular changes (Fig. 2) including increases in the expression of glial fibrillary acid protein (GFAP), vimentin, nestin and RhoA, glutamate uptake, protection against oxidative stress through the production of glutathione, neuroprotection by the release of adenosine, degradation of beta-amyloid peptides, regulation of the blood-brain barrier, and formation of glial scars. It is noteworthy that in some cases, reactive astrocytes can release inflammatory cytokines including tumor necrosis factor (TNF) and ROS [45, 53–57].

In the case of PD, there is conflicting information regarding the role of astrogliosis during disease onset. Some studies have shown that an increase in number of reactive astrocytes




Fig. 2 Rotenone and PDGF-BB effects in experimental models of PD. Various toxins have been used as experimental models in PD including paraquat or rotenone and neurotoxins such as 6-hydroxydopamine (6-OHDA) and MPP+. Paraquat, 6-OHDA, and MPP+ use the dopamine transporter (DA) to enter the dopaminergic neurons, whereas rotenone due to its lipophilic structure does not require this transporter. These toxins can induce cellular and molecular alterations including the inhibition of mitochondrial complex I, formation of aggregates of α -synuclein, decrease in ATP production, ROS overproduction, and release of pro-

apoptotic molecules such as cytochrome c. In turn, this molecule, in the cytosol, activates caspase 9 and triggers the canonical apoptotic activation in dopaminergic neurons (a). PDGF-BB decreases the damaging effects induced by rotenone at various levels, including modulation of intracellular calcium uptake, attenuated ROS production, regulation of morphological changes, mitochondrial protection, and activation of transcription factors such as NF- κ B, thus overexpressing neuroprotective molecules such as neuroglobin. Furthermore, neuroglobin (ngb1) has protective actions on mitochondria by controlling oxidative stress production (b)

is indicative of the importance of these cells in the repair of dopaminergic neurons [58, 59], while other studies have shown that the presence of reactive astrocytes in postmortem tissues of patients with PD is quite low [60, 61], the latter suggesting that excessive accumulation of α -synuclein could suppress the protection exerted by astrocytes. Therefore, it is necessary to carry out additional studies on astrocytic activation in the context of the development of PD, including clinical trials. On the other hand, different biological or environmental toxins have been used, especially herbicides and pesticides such as rotenone, paraquat, or MPTP in PD models, since these compounds can induce astrocyte reactivity and microgliosis, as well as neuronal death, mitochondrial dysfunction, oxidative stress, and nuclear fragmentation [62–67]. All these processes resemble what happen during the initial stages of PD [39]. The rotenone model of PD is discussed in more details in the next section.

The Rotenone Model of Parkinson's Disease

Rotenone is a highly lipophilic flavonoid extracted from the roots of the plants belonging to the genus *Derris* and *Lonchocarpus* of the Leguminosae family [68]. This molecule is well known as an insecticide, and its main mode of action is through the inhibition of electron transport in the mitochondrial complex I where it blocks the production of ATP, consequently affecting cellular metabolism [39, 69]. The immediate inhibition of the mitochondrial respiratory chain leads to an increase in the production of ROS such as hydrogen peroxide and superoxide radical together with the peroxidation of cell membrane and DNA damage [1, 5, 29, 69, 70]. The cellular and molecular effects caused by rotenone include the selective degeneration of the nigrostriatal dopaminergic system, activation of astroglia and microglia, formation and accumulation of an altered form of α -synuclein and Tau proteins associated with dopaminergic neuron damage (Fig. 2), stress of endoplasmic reticulum (UPR), overexpression of chaperones

(GRP78), alterations in axonal formation associated with decreased activity of Cdc42 and Rac, and activation of apoptotic pathways mediated by BAD and caspases 3 and 9 [1, 5, 39, 68, 71–76]. Likewise, it has been determined that rotenone can act independently of its inhibitory effects on complex I, for example, rotenone affects the stability of microtubules, inhibits the expression of connexin 43 and gap junction permeability in astrocytes, disturbs calcium homeostasis, and induces DNA damage or inflammatory responses and disruptive effects on cell cycle [77–79].

As a neurodegenerative model, rotenone has been used successfully in *in vitro* and *in vivo* studies of PD, due to the similarity between the cellular and molecular effects produced by this toxin and the symptoms of PD [39, 62, 63, 80]. For example, rotenone has been previously used in cell lines such as SH-SY5Y (human neuroblastoma) and animal models of PD [1, 5, 39, 62, 80]. In this regard, it has been reported that in mice and rats, continuous administration of rotenone mimics some of the characteristics of PD, including selective degeneration of dopaminergic neurons, mitochondrial dysfunction and increased ROS production, astrocyte and microglial activation, blood-brain barrier dysfunction, formation of neuronal cytoplasmic inclusions, anxiety-like behavior, defects in spatial memory, and motor disorders [1, 5, 39, 72, 73, 81–85]. Finally, in a study by the National Institute of Health (NIH), it was observed that people with exposure to rotenone are 2.5 times more likely to develop PD than those who are unexposed [80], and the use of gloves and other protective measures is important to prevent exposure to this pesticide [86]. Together, collected data suggest the relevance of using rotenone as a neurotoxic compound for assessing cell damage in neurodegenerative events. Along with rotenone, other compounds have been used in the experimental study of PD in both cellular and animal models (Fig. 2). These compounds include 6-OHDA (6-hydroxydopamine), the pesticide paraquat (N,N'-dimethyl-4,4'-bipyridinium dichloride), and MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a secondary metabolite produced from the synthesis of heroin [24, 38, 41, 87, 88].

Growth Factors and Neuroprotection

Several neurotrophic factors have been shown to protect neurons and glial cells against excitotoxicity and other neurodegenerative processes. For example, BDNF protects neurons against excitotoxicity by activating the transcription factor NF- κ B, which induces the expression of antioxidant enzymes such as Mn-SOD, glutathione reductase, the anti-apoptotic protein Bcl-2, and the inhibitors of apoptosis proteins (IAP; [16, 89]). Likewise, administration of BDNF has been reported to protect neurons in the substantia nigra against 6-OHDA and MPTP in parkinsonian models of mice and primates [17].

Another study has demonstrated that VEGF expression is upregulated in rat brain after treatment with 40 nM rotenone, an effect that is accompanied by an increase in neuronal survival [14]. The basic fibroblast growth factor (bFGF) protects cortical and hippocampal neurons against the toxicity of glutamate by changing the expression of NMDA receptors and antioxidant enzymes such as superoxide dismutase (SOD) and glutathione reductase [16]. Similarly, it has been reported that pretreatment with bFGF decreases rotenone-induced apoptosis in human neuroblastoma cells (SH-SY5Y) by the activation of ERK1/2 and phosphatidylinositol 3-kinase (PI3K) [90]. On the other hand, the glial cell line-derived neurotrophic factor (GDNF), secreted by astrocytes, increases neuronal dopaminergic resistance to 6-OHDA toxicity, indicating a role of this growth factor in neuroprotection [91]. Likewise, insulin-like growth factors (IGFs) can protect neurons against excitotoxicity in both *in vitro* and *in vivo* models through the activation of PI3K/Akt pathway [16, 92, 93]. In this aspect, it has been reported that IGF-I affects glucose metabolism in astrocytes and neurons in the adult brain through increased expression of transporters GLUT3 and 4, and thus boosting glucose uptake that can exert neuroprotective and antiapoptotic effects [92]. More recently, it has been shown that combined treatment with stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF) was able to improve several neurobehavioral parameters such as spatial learning and memory, posttraumatic anxiety, and risk-taking behavior in C57BL mice with traumatic brain injury (TBI) [94]. Moreover, the secretome of HEK-293 cells was used to reduce kainic acid neurotoxicity in murine hippocampal neurons through the activation of PI3K pathway and free radical scavenging mechanisms [95].

Other studies have used transplants of dopaminergic neurons or glial precursor cells in injured regions of the brain to increase the expression of growth factors such as BDNF, GDNF, and IGF, thus exerting a restorative effect [8, 96, 97]. For example, a study by Proschel et al. (2014) showed that the transplantation of glial precursor cells in rats injured with 6-OHDA caused the recovery of the DA neurons of the striatum together with an increase in the levels of GSH, GDNF, and BDNF [97]. Similarly, in our research group, the conditioned medium of mesenchymal stem cells was used to protect against oxidative injury induced by glucose deprivation in T98G astrocytic cells probably due to the presence of the growth factors, VEGF, IGF, PDGF-BB, and bFGF, in the conditioned medium [11, 98].

Platelet-Derived Growth Factor

PDGF is a homodimeric protein with approximately 30 kDa belonging to the family of PDGF/vascular endothelial growth factor (VEGF). Thus far, five dimeric compositions or isoforms have been identified: PDGF-AA, PDGF-BB, PDGF-

AB, PDGF-CC, and PDGF-DD [99, 100]. These five dimeric isoforms of PDGF show different affinities to the two tyrosine kinase receptors of PDGF, PDGFR α , and PDGFR β [101–103]. As in the case of most tyrosine kinase receptors, binding of the ligand and subsequent dimerization of the subunits promotes reciprocal phosphorylation of tyrosine residues in the intracellular domain of the receptor [99, 104]. The tyrosine kinase receptors PDGFR α and PDGFR β have a common structure with five extracellular immunoglobulin (IG)-type domains and an intracellular tyrosine kinase domain. This structure is shared with other receptor proteins such as c-Kit, c-Fms, and Flt [99, 105]. Once the receptor is phosphorylated, several signaling pathways and mediators can be activated, including mitogen-activated protein kinase (MAPK), PI3K, Wnt pathway, and phospholipase C (PLC). Additionally, it has been reported that different ligands of PDGF can induce the activation of transcription factors such as Nrf2 (nuclear factor (erythroid-derived 2)-like 2), STAT, ELK-1, c-jun/c-fos, HIF-1 α , and NF- κ B [99, 102, 106–110].

It has been established that PDGFR α and PDGFR β receptors have different functions in the organism following their activation [99, 111]. PDGFR α is involved in the control of gastrulation and the development of the lung, intestines, skin, testes, and kidney, while PDGFR β signaling plays important roles in early hematopoiesis and formation of blood vessels [111]. Current evidence shows that both homodimers and AB heterodimers can be generated, which bind with differential affinity to the receptors of the PDGF system (Andrae, 2008). PDGF-AA and PDGF-CC dimers bind to PDGFR α while PDGF-BB shows a greater affinity for PDGFR β , though it can also bind PDGFR α since this receptor has a greater structural promiscuity [99, 104]. On the other hand, PDGF-BB is an important mitogenic factor produced by different cell types such as platelets, megakaryocytes, fibroblasts, smooth muscle cells, neurons, oligodendrocytes, and astrocytes [100, 108, 112–116]. It has been found that PDGF-BB induces embryonic and vascular development, *in vivo* wound healing as well as regulation of chemotaxis, and cell transformation processes *in vitro* [99, 100].

PDGF-BB and Protective Mechanisms

The signaling mechanisms involved in the protective effects of PDGF-BB include the activation of antiapoptotic and survival pathways, such as MAPK, PI3K-AKT, JNK, and NF- κ B [109, 117, 118]. In this regard, it has been shown that the activation of these signaling pathways is dependent on the influx of calcium into the cell, which affects the phosphorylation of GSK3 β and β -catenin [21, 66]. Likewise, it has been suggested that PDGF-BB can activate mechanisms involved in the modification of the cytoskeleton and cell migration through phosphatidylinositol 3,4,5, which then activates the Rac GTPase protein of the Rho family, the latter being

involved in the modification of the actin cytoskeleton and morphological changes [119–121]. Additionally, it has been reported that treatment with PDGF-AB in injured fibroblasts increases the mitochondrial volume and the surface area of the crista ridges, suggesting that PDGF-AB can induce ultrastructural changes related to an increment in energy requirements, such as those produced during recovery from injuries [122]. Another signaling mechanism activated by PDGF ligands is mediated by the transcriptional activator STATs, which are important in processes such as proliferation, differentiation, survival, and cell transformation [108, 123]. The activation of STAT 1, 3, and 6 by PDGF ligands has been observed in vascular muscle cells in processes such as airway remodeling in patients with asthma [123]. This activation is apparently dependent on the production of H₂O₂ as a result of the activation of the transmembrane NOX enzyme (NADPH oxidase/dual oxidase enzyme), which is independent of ROS production by mitochondria [108, 123]. However, the involvement of different isoforms of PDGF in the production of ROS in the nervous system has neither been established, nor what the effects would be during this process. It is possible that production of hydrogen peroxide by PDGF ligands has beneficial effects as this is a second messenger in signaling pathways activated by the STATs, and is also involved in the regulation of downstream phosphatase proteins [108, 123, 124].

It has also been suggested that PDGF-BB can activate the NF- κ B transcription factor by regulating the PI3K/AKT pathway during cell growth, differentiation, apoptosis, and stress response, also decreasing the expression of genes such as matrix metalloproteinase 9 (MMP-9) and VEGF [109, 117]. On the other hand, the activation of PI3K/AKT leads to the inactivation of the kinase GSK3 β . In its inactivated form, GSK3 β prevents the degradation of β -catenin, increasing its accumulation in the cytoplasm and causing its translocation to the nucleus, where it can contribute to the activation of genes associated with cell survival [21]. Additionally, β -catenin is related to mitochondrial homeostasis, regulation of ATP production, and lipid oxidation [125, 126]. Likewise, Avila-Gómez et al. (2010) showed that IGF-I protects human lymphocytes by activating PI-3K/AKT, regulating p53, and maintaining $\Delta\Psi$ m [127]. Considering that IGF-I induces the activation of β -catenin by PI-3K/AKT [128], this activation could lead to a subsequent mitochondrial protection. In this aspect, previous studies in neuronal models have also shown that 24 h of pretreatment with PDGF-BB exerted significant protection against hydrogen peroxide, glucose deprivation, and excitotoxicity damage in cultured neurons [118, 129, 130]. Alternatively, it has been shown that PI3K/AKT exerts a negative regulation on the transcription factors FOXO (forkhead transcription factors), which are involved in cell survival, regulation of oxidative stress, and polarization of the mitochondrial membrane [131, 132], suggesting the importance of the PI3K/AKT pathway in these cellular events.

It has been suggested that different isoforms of PDGF possess important neuroprotective and regenerative functions in several research models [13, 18, 20–22, 114]. For example, increases in the PDGF-AA and PDGF-BB ligands and PDGFR α and PDGFR β receptors have been observed in cerebral samples from patients with ischemia [114, 133]. It was also shown that pretreatment with 120–240-ng/mL doses of PDGF-BB decreased the death of pyramidal neurons in rats during ischemic damage [20]. Likewise, it was determined that intracerebral administration of PDGF-BB decreased the lesion area due to overstimulation with NMDA in neonatal rats [134]. On the other hand, it has been reported that PDGF-CC protected murine neuronal cells against apoptotic death induced by different types of toxins including 6-OHDA and HIV TAT toxin [21, 22]. In recent years, Zachrisson et al. (2011) suggested restorative effects of PDGF-BB in dopaminergic neurons of rats injured with 6-OHDA and MPTP [18], and clinical trials in humans performed by the same group [13] did not produce adverse effects. Similarly, a recent study by Osborne et al. (2018) showed that PDGF-AB produced by human mesenchymal stem cells (hMSC) reduced optic nerve injury in human explants [135]. Moreover, it was recently observed that PDGF-BB used as pretreatment (200 ng/mL) was able to protect human astrocytic cells T98G against rotenone (50 μ M) via reducing the production of superoxide and peroxide radicals, maintenance of $\Delta\psi_m$ (mitochondrial membrane potential) and mitochondrial ultrastructure, and activation of the PI3K/AKT signaling pathway [136–138].

Another important aspect of PDGF-BB is its ability to modulate cell morphology. In this regard, it has been shown that PDGF-BB induces lamellipodia formation and increases fibroblast motility mediated by rearrangements of actin fibers, these processes being dependent on PI3K kinase [139, 140]. It has also been observed that the expression of the PDGFR β receptor is necessary for the development of the embryonic neural crest, astrocytic development and differentiation, and the morphogenesis and plasticity of dendritic spines [113, 141]. Indeed, growth factors such as PDGF-BB and VEGF induce the activation of RhoA protein in endothelial cells during the angiogenesis process [121, 142]. In the case of astrocytes, the inactivation of RhoA by clostridium botulinum C3 toxin induces irreversible changes in the cytoskeleton, therefore generating a star-shaped astrocyte morphology associated with the disassembly of actin and intermediate filaments [143]. Likewise, it has been pointed out that increase of peroxides and nitric oxide causes the activation of Rho/ROCK in vascular models [144, 145]. In this aspect, Fujimura and Usuki (2012) found that exposure to 100 nM rotenone or inorganic mercury inhibited the expression of the protein CDC42 and Rac1 without affecting the expression of RhoA, together with axonal degeneration and cortical brain cell death [146]. Likewise, it has been demonstrated that pharmacological inhibition of ROCK kinase decreases the phosphorylation

of ERK1/2, even after stimulation with PDGF-BB in glioblastoma cells [147].

Several studies have suggested that PDGF-BB signaling is regulated in part by intracellular calcium concentration, both in normal and pathological conditions [21, 148–150]. In this regard, it has been determined that PDGF-BB also activates phospholipase C causing the formation of inositol triphosphate (IP3) and diacylglycerol (DAG), which increases the mobilization of Ca²⁺ from intracellular compartments and leads to the activation of protein kinase C [149, 150]. Additionally, PDGF-CC protects against TAT toxin from HIV by activating the transient potential channel 1 (TRPC) channels, which modulates the downstream protein pathway such as GSK3 β [21], in the SH-SY5Y neuroblastoma line. These studies suggest that the PDGF family of growth factors, especially PDGF-BB, might have important neuroprotective properties. The protective mechanisms activated by PDGF-BB in the brain are summarized in Fig. 2.

Neuroglobin Activation by Growth Factors

In recent years, the neuroglobin protein (ngb1) has been assessed in both neurons and astrocytes due to its multiple functions relevant to neuroprotection in pathologies such as focal ischemia, AD, apoplexy, and traumatic brain injury [10, 151–154]. Ngb1 has 150 aa and a molecular weight of 18 kDa, containing a heme group which allows it to transport and store oxygen in different organs such as the retina and the brain [155]. It has been suggested that this protein has other functions such as signaling during hypoxia, serving as NADH oxidase, elimination of ROS, regulation of calcium levels, mitochondrial regulation, and neuroregeneration following optic nerve injury in mice [151, 156–159]. At the genetic level, it has been observed that the gene promoter region of neuroglobin can be regulated by transcription factors such as hypoxia-inducible factor 1- α (HIF-1 α), SP1, CREB, and NF- κ B, which are related to cellular response to hypoxia [160–162]. However, the most studied function of neuroglobin is adaptation to hypoxia which has been studied in various animal models and cell lines [151, 163, 164]. In this aspect, it is known that under normoxic conditions neuroglobin is bound to oxygen, while under hypoxic conditions, this protein adopts a hexacoordinated structure of the heme group. This hexacoordinated structure allows rapid transfer of electrons between ferrous neuroglobin and ferric cytochrome during hypoxia. Hence, by rapidly reducing ferric cytochrome c, non-apoptotic levels of ferrous cytochrome c would be maintained, which would decrease apoptotic activation, thus exerting a potentially neuroprotective effect [164–166]. Likewise, it has been shown that neuroglobin overexpression increase the antiapoptotic signaling and the reduction of movement disorders in transgenic models of mice in conditions of hypoxia and ischemia [167, 168].

It has been reported that neuroglobin can be translocated to the mitochondria, where it interacts with proteins such as the Atp1b1 and Atp1b3 subunits of Na^+/K^+ ATPase, cytochrome c (Cyc1), electron-transfer-flavoprotein, alpha polypeptide (Etf α), and voltage-dependent anionic channel (VDAC), suggesting its importance in mitochondrial protection [169, 170]. Interestingly, neuroglobin silencing by siRNA impairs $\Delta\psi_m$ maintenance and leads to increased ROS levels in both astrocytes and neurons [10, 151, 171]. Likewise, it has been suggested that neuroglobin could regulate mitochondrial calcium levels in human neuroblastoma SH-SY5Y cells, which might also be related to a decrease in the activation of apoptotic pathways [157, 172]. Finally, it has been recently shown that neuroglobin is able to protect mitochondria against MPP+ treatment in neuroblastoma SK-N-BE2 cells through its association with lipid raft complexes [173].

Several conditions are known to be involved in the regulation and expression of neuroglobin. These include hypoxia and ischemia, glucose deprivation, hormonal treatments, vascular endothelial growth factor (VEGF) and the use of conditioned medium of mesenchymal stem cells derived from human adipose tissue [10, 11, 151, 164, 170]. For example, it was observed that VEGF stimulated the expression of *ngb1* in cortical neuronal cultures of embryonic mice through activation of the VEGFR2/Flk1 receptor [174]. It was also shown that both transforming growth factor- β 1 (TGF β 1) and PDGF-BB increased the expression of the cytoglobin protein in hepatic stellate cells [175]. Finally, it was reported by our group that PDGF-BB increases GPx1 and neuroglobin expression in an astrocytic model during rotenone insult [138], suggesting the importance of PDGF-BB and other growth factors in neuroglobin modulation.

Conclusions

Previous studies have demonstrated the protective effects of PDGF-BB and other growth factors in neurons and astrocytic cells against oxidative stress. In this aspect, PDGF-BB was shown to improve mitochondrial protection at the functional level by activating proteins such as neuroglobin and GPx1. Hence, the available evidence suggests that PDGF-BB-induced signaling pathways may be relevant for the preservation of mitochondrial function. Additional studies in astrocytic primary cultures, in vivo models, and extended clinical trials are needed to clarify the underlying mechanisms and molecular signature through which PDGF-BB interacts with mitochondria and confers protection to astrocytes and neurons. It is also important to establish which proteins might be interacting with neuroglobin within mitochondria in order to better decipher this protective mechanism of PDGF-BB against oxidative stress.

Funding Information This work was supported in part by PUJ grants to GEB.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

References

- Liu B, Gao HM, Hong JS (2003) Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. *Environ Health Perspect* 111(8):1065–1073
- Dos Santos AB, Barreto GE, Kohlmeier KA (2014) Treatment of sleeping disorders should be considered in clinical management of Parkinson's disease. *Front Aging Neurosci* 6:273
- dos Santos AB, Kohlmeier KA, Barreto GE (2015) Are sleep disturbances preclinical markers of Parkinson's disease? *Neurochem Res* 40(3):421–427
- Halliday GM, Stevens CH (2011) Glia: initiators and progressors of pathology in Parkinson's disease. *Mov Disord* 26(1):6–17
- Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, Robinson JP (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. *J Biol Chem* 278(10):8516–8525
- Nutt JG, Wooten GF (2005) Clinical practice. diagnosis and initial management of Parkinson's disease. *N Engl J Med* 353(10):1021–1027
- Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkman J, Stefani A, Horak FB, Okun MS et al (2011) Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. *Arch Neurol* 68(2):165
- Hauser RA, McDermott MP, Messing S (2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. *Arch Neurol* 63(12):1756–1760
- Post B, Muslimovic D, van Geloven N, Speelman JD, Schmand B, de Haan RJ, C.A.-s. group (2011) Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease. *Mov Disord* 26(3):449–456
- Avila-Rodriguez M, Garcia-Segura LM, Hidalgo-Lanussa O, Baez E, Gonzalez J, Barreto GE (2016) Tibolone protects astrocytic cells from glucose deprivation through a mechanism involving estrogen receptor beta and the upregulation of neuroglobin expression. *Mol Cell Endocrinol* 433:35–46
- Baez-Jurado E, Vega GG, Aliev G, Tarasov VV, Esquinas P, Echeverria V, Barreto GE (2018) Blockade of neuroglobin reduces protection of conditioned medium from human mesenchymal stem cells in human astrocyte model (T98G) under a scratch assay. *Mol Neurobiol* 55(3):2285–2300
- Correia AS, Anisimov SV, Li JY, Brundin P (2005) Stem cell-based therapy for Parkinson's disease. *Ann Med* 37(7):487–498
- Paul G, Zachrisson O, Varrone A, Almqvist P, Jerling M, Lind G, Rehnroth S, Linderth B et al (2015) Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients. *J Clin Invest* 125(3):1339–1346
- Falk T, Zhang S, Sherman SJ (2009) Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. *Mol Neurodegener* 4:49
- Henriques A, Pitzer C, Schneider A (2010) Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? *Front Neurosci* 4:32

16. Mattson MP (2008) Glutamate and neurotrophic factors in neuronal plasticity and disease. *Ann N Y Acad Sci* 1144:97–112
17. Ramaswamy S, Kordower JH (2009) Are growth factors the answer? *Parkinsonism Relat Disord* 15(Suppl 3):S176–S180
18. Zachrisson O, Zhao M, Andersson A, Danneus K, Haggblad J, Isacson R, Nielsen E, Patrone C et al (2011) Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. *J Parkinson's Dis* 1(1):49–63
19. Weissmiller AM, Wu C (2012) Current advances in using neurotrophic factors to treat neurodegenerative disorders. *Transl Neurodegener* 1(1):14
20. Iihara K, Hashimoto N, Tsukahara T, Sakata M, Yanamoto H, Taniguchi T (1997) Platelet-derived growth factor-BB, but not -AA, prevents delayed neuronal death after forebrain ischemia in rats. *J Cereb Blood Flow Metab* 17(10):1097–1106
21. Peng F, Yao H, Akturk HK, Buch S (2012) Platelet-derived growth factor CC-mediated neuroprotection against HIV Tat involves TRPC-mediated inactivation of GSK 3beta. *PLoS One* 7(10):e47572
22. Tang Z, Arjunan P, Lee C, Li Y, Kumar A, Hou X, Wang B, Wardega P et al (2010) Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation. *J Exp Med* 207(4):867–880
23. Ahmed Z, Asi YT, Lees AJ, Revesz T, Holton JL (2013) Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson's disease. *Brain Pathol* 23(3):263–273
24. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. *Mov Disord* 23(4):474–483
25. Mena MA, Garcia de Yebenes J (2008) Glial cells as players in parkinsonism: the “good,” the “bad,” and the “mysterious” glia. *Neuroscientist* 14(6):544–560
26. More SV, Kumar H, Kim IS, Song SY, Choi DK (2013) Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. *Mediat Inflamm* 2013:952375
27. Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH, Jin BK (2010) The role of neuroinflammation on the pathogenesis of Parkinson's disease. *BMB Rep* 43(4):225–232
28. Barreto GE, Gonzalez J, Torres Y, Morales L (2011) Astrocytic-neuronal crosstalk: implications for neuroprotection from brain injury. *Neurosci Res* 71(2):107–113
29. Cabezas R, El-Bacha RS, Gonzalez J, Barreto GE (2012) Mitochondrial functions in astrocytes: neuroprotective implications from oxidative damage by rotenone. *Neurosci Res* 74(2):80–90
30. Contreras L, Drago I, Zampese E, Pozzan T (2010) Mitochondria: the calcium connection. *Biochim Biophys Acta* 1797(6–7):607–618
31. Simpkins JW, Yi KD, Yang SH, Dykens JA (2010) Mitochondrial mechanisms of estrogen neuroprotection. *Biochim Biophys Acta* 1800(10):1113–1120
32. Knott AB, Bossy-Wetzel E (2008) Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration. *Ann N Y Acad Sci* 1147:283–292
33. Wang HL, Chou AH, Wu AS, Chen SY, Weng YH, Kao YC, Yeh TH, Chu PJ et al (2011) PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. *Biochim Biophys Acta* 1812(6):674–684
34. Gorbatyuk MS, Shabashvili A, Chen W, Meyers C, Sullivan LF, Salganik M, Lin JH, Lewin AS et al (2012) Glucose regulated protein 78 diminishes alpha-synuclein neurotoxicity in a rat model of Parkinson disease. *Mol Ther* 20(7):1327–1337
35. Hashida K, Kitao Y, Sudo H, Awa Y, Maeda S, Mori K, Takahashi R, Iinuma M et al (2012) ATF6alpha promotes astroglial activation and neuronal survival in a chronic mouse model of Parkinson's disease. *PLoS One* 7(10):e47950
36. Varma D, Sen D (2015) Role of the unfolded protein response in the pathogenesis of Parkinson's disease. *Acta Neurobiol Exp* 75(1):1–26
37. Wang M, Wey S, Zhang Y, Ye R, Lee AS (2009) Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. *Antioxid Redox Signal* 11(9):2307–2316
38. Berry C, La Vecchia C, Nicotera P (2010) Paraquat and Parkinson's disease. *Cell Death Differ* 17(7):1115–1125
39. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. *Nat Neurosci* 3(12):1301–1306
40. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, Dicke A, Kusnekov A (2010) The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. *Psychosomatics* 51(6):474–479
41. Wachter B, Schurger S, Rolinger J, von Ameln-Mayerhofer A, Berg D, Wagner HJ, Kueppers E (2010) Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: evidence for de-differentiation of resident astrocytes. *Cell Tissue Res* 342(2):147–160
42. Klingelhoefer L, Reichmann H (2015) Pathogenesis of Parkinson disease—the gut-brain axis and environmental factors. *Nat Rev Neurol* 11(11):625–636
43. Chen Y, Swanson RA (2003) Astrocytes and brain injury. *J Cereb Blood Flow Metab* 23(2):137–149
44. Bushong EA, Martone ME, Jones YZ, Ellisman MH (2002) Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. *J Neurosci* 22(1):183–192
45. Hamby ME, Sofroniew MV (2010) Reactive astrocytes as therapeutic targets for CNS disorders. *Neurotherapeutics* 7(4):494–506
46. Kimelberg HK, Nedergaard M (2010) Functions of astrocytes and their potential as therapeutic targets. *Neurotherapeutics* 7(4):338–353
47. Pappas V, Grubisic V, Verkhratsky A (2011) Ca(2+) sources for the exocytotic release of glutamate from astrocytes. *Biochim Biophys Acta* 1813(5):984–991
48. Volterra A, Meldolesi J (2005) Astrocytes, from brain glue to communication elements: the revolution continues. *Nat Rev Neurosci* 6(8):626–640
49. Greve MW, Zink BJ (2009) Pathophysiology of traumatic brain injury. *Mt Sinai J Med* 76(2):97–104
50. Barreto GE, White RE, Xu L, Palm CJ, Giffard RG (2012) Effects of heat shock protein 72 (Hsp72) on evolution of astrocyte activation following stroke in the mouse. *Exp Neurol* 238(2):284–296
51. Barreto GE, Sun X, Xu L, Giffard RG (2011) Astrocyte proliferation following stroke in the mouse depends on distance from the infarct. *PLoS One* 6(11):e27881
52. Barreto G, White RE, Ouyang Y, Xu L, Giffard RG (2011) Astrocytes: targets for neuroprotection in stroke. *Cent Nerv Syst Agents Med Chem* 11(2):164–173
53. Duffy P, Schmandke A, Schmandke A, Sigworth J, Narumiya S, Cafferty WB, Strittmatter SM (2009) Rho-associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord. *J Neurosci* 29(48):15266–15276
54. Fitch MT, Silver J (2008) CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. *Exp Neurol* 209(2):294–301
55. Jarlestedt K, Rousset CI, Faiz M, Wilhelmsson U, Stahlberg A, Sourkova H, Pekna M, Mallard C et al (2010) Attenuation of reactive gliosis does not affect infarct volume in neonatal hypoxic-ischemic brain injury in mice. *PLoS One* 5(4):e10397

56. Kang W, Hebert JM (2011) Signaling pathways in reactive astrocytes, a genetic perspective. *Mol Neurobiol* 43(3):147–154
57. Sugaya K, Chou S, Xu SJ, McKinney M (1998) Indicators of glial activation and brain oxidative stress after intraventricular infusion of endotoxin. *Brain Res Mol Brain Res* 58(1–2):1–9
58. Chen LW, Yung KL, Chan YS (2005) Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease. *Curr Drug Targets* 6(7):821–833
59. Episcopo FL, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B (2013) Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson's disease: focus on endogenous neurorestoration. *Curr Aging Sci* 6(1):45–55
60. Song YJ, Halliday GM, Holton JL, Lashley T, O'Sullivan SS, McCann H, Lees AJ, Ozawa T et al (2009) Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. *J Neuropathol Exp Neurol* 68(10):1073–1083
61. Tong J, Ang LC, Williams B, Furukawa Y, Fitzmaurice P, Guttman M, Boileau I, Hornykiewicz O et al (2015) Low levels of astroglial markers in Parkinson's disease: relationship to alpha-synuclein accumulation. *Neurobiol Dis* 82:243–253
62. de Oliveira DM, Barreto G, Galeano P, Romero JI, Holubiec MI, Badorrey MS, Capani F, Alvarez LD (2011) *Paullinia cupana* Mart. var. *Sorbilis* protects human dopaminergic neuroblastoma SH-SY5Y cell line against rotenone-induced cytotoxicity. *Hum Exp Toxicol* 30(9):1382–1391
63. de Oliveria DM, Barreto G, De Andrade DV, Saraceno E, Aon-Bertolino L, Capani F, Dos Santos R, El Bacha LDG (2009) Cytoprotective effect of *Valeriana officinalis* extract on an in vitro experimental model of Parkinson disease. *Neurochem Res* 34(2):215–220
64. Niranjana R, Nath C, Shukla R (2010) The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6. *Free Radic Res* 44(11):1304–1316
65. Samantaray S, Knaryan VH, Guyton MK, Matzelle DD, Ray SK, Banik NL (2007) The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. *Neuroscience* 146(2):741–755
66. Zhu X, Yao H, Peng F, Callen S, Buch S (2009) PDGF-mediated protection of SH-SY5Y cells against Tat toxin involves regulation of extracellular glutamate and intracellular calcium. *Toxicol Appl Pharmacol* 240(2):286–291
67. Valverde GDAD, Madureira de Oliveria D, Barreto G, Bertolino LA, Saraceno E, Capani F, Giraldez LD (2008) Effects of the extract of *Anemopaegma mirandum* (Catuaba) on rotenone-induced apoptosis in human neuroblastomas SH-SY5Y cells. *Brain Res* 1198:188–196
68. Isman MB (2006) Botanical insecticides, deterrents, and repellents in modern agriculture and an increasingly regulated world. *Annu Rev Entomol* 51:45–66
69. Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G, Ellinger-Ziegelbauer H (2017) Mechanistic investigations of the mitochondrial complex I inhibitor rotenone in the context of pharmacological and safety evaluation. *Sci Rep* 7:45465
70. Swarnkar S, Singh S, Goswami P, Mathur R, Patro IK, Nath C (2012) Astrocyte activation: a key step in rotenone induced cytotoxicity and DNA damage. *Neurochem Res* 37(10):2178–2189
71. Chen YY, Chen G, Fan Z, Luo J, Ke ZJ (2008) GSK3beta and endoplasmic reticulum stress mediate rotenone-induced death of SK-N-MC neuroblastoma cells. *Biochem Pharmacol* 76(1):128–138
72. Hoglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Feger J, Champy P, Prigent A et al (2005) The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. *J Neurochem* 95(4):930–939
73. Ogawa N, Asanuma M, Miyazaki I, Diaz-Corrales FJ, Miyoshi K (2005) L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease. *J Neurol* 252(Suppl 4):IV23–IV31
74. Sanchez M, Gastaldi L, Remedi M, Caceres A, Landa C (2008) Rotenone-induced toxicity is mediated by Rho-GTPases in hippocampal neurons. *Toxicol Sci* 104(2):352–361
75. Tiwari M, Lopez-Cruzan M, Morgan WW, Herman B (2011) Loss of caspase-2-dependent apoptosis induces autophagy after mitochondrial oxidative stress in primary cultures of young adult cortical neurons. *J Biol Chem* 286(10):8493–8506
76. Watabe M, Nakaki T (2004) Rotenone induces apoptosis via activation of bad in human dopaminergic SH-SY5Y cells. *J Pharmacol Exp Ther* 311(3):948–953
77. Cabeza-Arvelaiz Y, Schiestl RH (2012) Transcriptome analysis of a rotenone model of parkinsonism reveals complex I-tied and -untied toxicity mechanisms common to neurodegenerative diseases. *PLoS One* 7(9):e44700
78. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T et al (2003) Mechanism of toxicity in rotenone models of Parkinson's disease. *J Neurosci* 23(34):10756–10764
79. Zhang S, Liang R, Zhou F, Huang X, Ding JH, Hu G (2011) Reversal of rotenone-induced dysfunction of astrocytic connexin43 by opening mitochondrial ATP-sensitive potassium channels. *Cell Mol Neurobiol* 31(1):111–117
80. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS et al (2011) Rotenone, paraquat, and Parkinson's disease. *Environ Health Perspect* 119(6):866–872
81. Cabezas R, Avila M, Gonzalez J, El-Bacha RS, Baez E, Garcia-Segura LM, Jurado Coronel JC, Capani F et al (2014) Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. *Front Cell Neurosci* 8:211
82. Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG (2010) Lessons from the rotenone model of Parkinson's disease. *Trends Pharmacol Sci* 31(4):141–142 author reply 142–3
83. Johnson ME, Bobrovskaya L (2015) An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. *Neurotoxicology* 46:101–116
84. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G et al (2010) Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. *PLoS One* 5(1):e8762
85. Perier C, Vila M (2012) Mitochondrial biology and Parkinson's disease. *Cold Spring Harb Perspect Med* 2(2):a009332
86. Furlong M, Tanner CM, Goldman SM, Bhudhikanok GS, Blair A, Chade A, Comyns K, Hoppin JA et al (2015) Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease. *Environ Int* 75:144–150
87. Bove J, Prou D, Perier C, Przedborski S (2005) Toxin-induced models of Parkinson's disease. *NeuroRx* 2(3):484–494
88. Sonsalla PK, Zeevalk GD, German DC (2008) Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease. *Parkinsonism Relat Disord* 14(Suppl 2):S116–S118
89. Lee S, Williamson J, Lothman EW, Szele FG, Chesselet MF, Von Hagen S, Sapolsky RM, Mattson MP et al (1997) Early induction of mRNA for calbindin-D28k and BDNF but not NT-3 in rat hippocampus after kainic acid treatment. *Brain Res Mol Brain Res* 47(1–2):183–194
90. Hsuan SL, Klintworth HM, Xia Z (2006) Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death

- through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways. *J Neurosci* 26(17):4481–4491
91. Safi R, Gardaneh M, Panahi Y, Maghsoudi N, Zaefizadeh M, Gharib E (2012) Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity. *J Mol Neurosci* 46(3):654–665
 92. Aberg ND, Brywe KG, Isgaard J (2006) Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. *Sci World J* 6:53–80
 93. Pang Y, Zheng B, Campbell LR, Fan LW, Cai Z, Rhodes PG (2010) IGF-1 can either protect against or increase LPS-induced damage in the developing rat brain. *Pediatr Res* 67(6):579–584
 94. Toshkezi G, Kyle M, Longo SL, Chin LS, Zhao LR (2018) Brain repair by hematopoietic growth factors in the subacute phase of traumatic brain injury. *J Neurosurg* 1–9. <https://doi.org/10.3171/2017.7.JNS17878>
 95. Venugopal C, Prasad YSHC, Shobha K, Pinnelli VB, Dhanushkodi A (2017) HEK-293 secretome attenuates kainic acid neurotoxicity through insulin like growth factor-phosphatidylinositol-3-kinases pathway and by temporal regulation of antioxidant defense machineries. *Neurotoxicology*. <https://doi.org/10.1016/j.neuro.2017.11.010>
 96. Jankovic J, Poewe W (2012) Therapies in Parkinson's disease. *Curr Opin Neurol* 25(4):433–447
 97. Proschel C, Stripay JL, Shih CH, Munger JC, Noble MD (2014) Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons. *EMBO Mol Med* 6(4):504–518
 98. Torrente D, Avila MF, Cabezas R, Morales L, Gonzalez J, Samudio I, Barreto GE (2014) Paracrine factors of human mesenchymal stem cells increase wound closure and reduce reactive oxygen species production in a traumatic brain injury in vitro model. *Hum Exp Toxicol* 33(7):673–684
 99. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. *Genes Dev* 22(10):1276–1312
 100. Yu J, Ustach C, Kim HR (2003) Platelet-derived growth factor signaling and human cancer. *J Biochem Mol Biol* 36(1):49–59
 101. Fredriksson L, Li H, Eriksson U (2004) The PDGF family: four gene products form five dimeric isoforms. *Cytokine Growth Factor Rev* 15(4):197–204
 102. Heldin CH, Ostman A, Ronnstrand L (1998) Signal transduction via platelet-derived growth factor receptors. *Biochim Biophys Acta* 1378(1):F79–F113
 103. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. *Physiol Rev* 79(4):1283–1316
 104. Torrente D, Cabezas R, Avila M, Sanchez Y, Morales L, Ashraf GM, Barreto GE, Gonzalez J et al (2015) Mechanisms of PDGFRalpha promiscuity and PDGFRbeta specificity in association with PDGFB. *Front Biosci* 7:434–446
 105. Kazlauskas A, Cooper JA (1989) Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins. *Cell* 58(6):1121–1133
 106. Ashino T, Yamamoto M, Yoshida T, Numazawa S (2013) Redox-sensitive transcription factor Nrf2 regulates vascular smooth muscle cell migration and neointimal hyperplasia. *Arterioscler Thromb Vasc Biol* 33(4):760–768
 107. Iqbal S, Zhang S, Driss A, Liu ZR, Kim HR, Wang Y, Ritenour C, Zhou HE et al (2012) PDGF upregulates Mcl-1 through activation of beta-catenin and HIF-1alpha-dependent signaling in human prostate cancer cells. *PLoS One* 7(1):e30764
 108. Kang SW (2007) Two axes in platelet-derived growth factor signaling: tyrosine phosphorylation and reactive oxygen species. *Cell Mol Life Sci* 64(5):533–541
 109. Romashkova JA, Makarov SS (1999) NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. *Nature* 401(6748):86–90
 110. Shin HW, Park SY, Lee KB, Shin E, Nam SW, Lee JY, Jang JJ (2009) Transcriptional profiling and Wnt signaling activation in proliferation of human hepatic stellate cells induced by PDGF-BB. *Korean J Hepatol* 15(4):486–495
 111. Shim AH, Liu H, Focia PJ, Chen X, Lin PC, He X (2010) Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. *Proc Natl Acad Sci U S A* 107(25):11307–11312
 112. Board R, Jayson GC (2005) Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. *Drug Resist Updat* 8(1–2):75–83
 113. Funa K, Sasahara M (2014) The roles of PDGF in development and during neurogenesis in the normal and diseased nervous system. *J Neuroimmune Pharmacol* 9(2):168–181
 114. Krupinski J, Issa R, Bujny T, Slevin M, Kumar P, Kumar S, Kaluza J (1997) A putative role for platelet-derived growth factor in angiogenesis and neuroprotection after ischemic stroke in humans. *Stroke* 28(3):564–573
 115. Trojanowska M (2008) Role of PDGF in fibrotic diseases and systemic sclerosis. *Rheumatology* 47(Suppl 5):v2–v4
 116. Yu JC, Lokker NA, Hollenbach S, Apatira M, Li J, Betz A, Sedlock D, Oda S et al (2001) Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. *J Pharmacol Exp Ther* 298(3):1172–1178
 117. Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, Sarkar FH (2010) Emerging roles of PDGF-D signaling pathway in tumor development and progression. *Biochim Biophys Acta* 1806(1):122–130
 118. Zheng L, Ishii Y, Tokunaga A, Hamashima T, Shen J, Zhao QL, Ishizawa S, Fujimori T et al (2010) Neuroprotective effects of PDGF against oxidative stress and the signaling pathway involved. *J Neurosci Res* 88(6):1273–1284
 119. Ball SG, Shuttleworth A, Kielty CM (2012) Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency. *Stem Cells* 30(3):548–560
 120. Li L, Li J, Wang JY, Yang CQ, Jia ML, Jiang W (2010) Role of RhoA in platelet-derived growth factor-BB-induced migration of rat hepatic stellate cells. *Chin Med J* 123(18):2502–2509
 121. Nobes CD, Hawkins P, Stephens L, Hall A (1995) Activation of the small GTP-binding proteins rho and rac by growth factor receptors. *J Cell Sci* 108(Pt 1):225–233
 122. Gossiau A, Dittich W, Willig A, Jaros PP (2001) Cytological effects of platelet-derived growth factor on mitochondrial ultrastructure in fibroblasts. *Comp Biochem Physiol A Mol Integr Physiol* 128(2):241–249
 123. Simon AR, Takahashi S, Severgnini M, Fanburg BL, Cochran BH (2002) Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol* 282(6):L1296–L1304
 124. Thannickal VJ, Fanburg BL (2000) Reactive oxygen species in cell signaling. *Am J Physiol Lung Cell Mol Physiol* 279(6):L1005–L1028
 125. Arrazola MS, Silva-Alvarez C, Inestrosa NC (2015) How the Wnt signaling pathway protects from neurodegeneration: the mitochondrial scenario. *Front Cell Neurosci* 9:166
 126. Lehwald N, Tao GZ, Jang KY, Papandreou I, Liu B, Liu B, Pysz MA, Willmann JK et al (2012) Beta-catenin regulates hepatic mitochondrial function and energy balance in mice. *Gastroenterology* 143(3):754–764

127. Avila-Gomez IC, Velez-Pardo C, Jimenez-Del-Rio M (2010) Effects of insulin-like growth factor-1 on rotenone-induced apoptosis in human lymphocyte cells. *Basic Clin Pharmacol Toxicol* 106(1):53–61
128. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C, Capeau J (2001) Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. *Oncogene* 20(2):252–259
129. Cheng B, Mattson MP (1995) PDGFs protect hippocampal neurons against energy deprivation and oxidative injury: evidence for induction of antioxidant pathways. *J Neurosci* 15(11):7095–7104
130. Tseng HC, Dichter MA (2005) Platelet-derived growth factor-BB pretreatment attenuates excitotoxic death in cultured hippocampal neurons. *Neurobiol Dis* 19(1–2):77–83
131. Burgering BM, Medema RH (2003) Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. *J Leukoc Biol* 73(6):689–701
132. Kato M, Yuan H, Xu ZG, Lanting L, Li SL, Wang M, Hu MC, Reddy MA et al (2006) Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. *J Am Soc Nephrol* 17(12):3325–3335
133. Sakata M, Yanamoto H, Hashimoto N, Iihara K, Tsukahara T, Taniguchi T, Kikuchi H (1998) Induction of infarct tolerance by platelet-derived growth factor against reversible focal ischemia. *Brain Res* 784(1–2):250–255
134. Egawa-Tsuzuki T, Ohno M, Tanaka N, Takeuchi Y, Uramoto H, Faigle R, Funa K, Ishii Y et al (2004) The PDGF B-chain is involved in the ontogenic susceptibility of the developing rat brain to NMDA toxicity. *Exp Neurol* 186(1):89–98
135. Osborne A, Sanderson J, Martin KR (2018) Neuroprotective effects of human mesenchymal stem cells and platelet-derived growth factor on human retinal ganglion cells. *Stem Cells* 36(1):65–78
136. Cabezas R, Avila MF, Gonzalez J, El-Bacha RS, Barreto GE (2015) PDGF-BB protects mitochondria from rotenone in T98G cells. *Neurotox Res* 27(4):355–367
137. Cabezas R, Avila-Rodriguez M, Vega-Vela NE, Echeverria V, Gonzalez J, Hidalgo OA, Santos AB, Aliev G et al (2016) Growth factors and astrocytes metabolism: possible roles for platelet derived growth factor. *Med Chem* 12(3):204–210
138. Cabezas R, Vega-Vela NE, Gonzalez-Sanmiguel J, Gonzalez J, Esquinas P, Echeverria V, Barreto GE (2018) PDGF-BB preserves mitochondrial morphology, attenuates ROS production, and upregulates neuroglobin in an astrocytic model under rotenone insult. *Mol Neurobiol* 55(4):3085–3095
139. Hedberg KM, Bengtsson T, Safiejko-Mroccka B, Bell PB, Lindroth M (1993) PDGF and neomycin induce similar changes in the actin cytoskeleton in human fibroblasts. *Cell Motil Cytoskeleton* 24(2):139–149
140. Ruusala A, Sundberg C, Arvidsson AK, Rupp-Thureson E, Heldin CH, Claesson-Welsh L (1998) Platelet-derived growth factor (PDGF)-induced actin rearrangement is deregulated in cells expressing a mutant Y778F PDGF beta-receptor. *J Cell Sci* 111(Pt 1):111–120
141. Svitkina T, Lin WH, Webb DJ, Yasuda R, Wayman GA, Van Aelst L, Soderling SH (2010) Regulation of the postsynaptic cytoskeleton: Roles in development, plasticity, and disorders. *J Neurosci* 30(45):14937–14942
142. van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW (2003) Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. *Arterioscler Thromb Vasc Biol* 23(2):211–217
143. Ramakers GJ, Moolenaar WH (1998) Regulation of astrocyte morphology by RhoA and lysophosphatidic acid. *Exp Cell Res* 245(2):252–262
144. Kagiya S, Matsumura K, Goto K, Otsubo T, Iida M (2010) Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice. *Regul Pept* 160(1–3):133–139
145. Noma K, Goto C, Nishioka K, Jitsuiki D, Umemura T, Ueda K, Kimura M, Nakagawa K et al (2007) Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. *J Am Coll Cardiol* 49(6):698–705
146. Fujimura M, Usuki F (2012) Differing effects of toxicants (methylmercury, inorganic mercury, lead, amyloid beta, and rotenone) on cultured rat cerebrocortical neurons: differential expression of rho proteins associated with neurotoxicity. *Toxicol Sci* 126(2):506–514
147. Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M (2009) Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. *Anticancer Res* 29(1):119–123
148. Pinzani M (2002) PDGF and signal transduction in hepatic stellate cells. *Front Biosci* 7:d1720–d1726
149. Powis G, Seewald MJ, Sehgal I, Iazzo PA, Olsen RA (1990) Platelet-derived growth factor stimulates non-mitochondrial Ca²⁺ uptake and inhibits mitogen-induced Ca²⁺ signaling in Swiss 3T3 fibroblasts. *J Biol Chem* 265(18):10266–10273
150. Ridefelt P, Yokote K, Claesson-Welsh L, Siegbahn A (1995) PDGF-BB triggered cytoplasmic calcium responses in cells with endogenous or stably transfected PDGF beta-receptors. *Growth Factors* 12(3):191–201
151. Baez E, Echeverria V, Cabezas R, Avila-Rodriguez M, Garcia-Segura LM, Barreto GE (2016) Protection by neuroglobin expression in brain pathologies. *Front Neurol* 7:146
152. Chen X, Liu Y, Zhang L, Zhu P, Zhu H, Yang Y, Guan P (2015) Long-term neuroglobin expression of human astrocytes following brain trauma. *Neurosci Lett* 606:194–199
153. Emara M, Salloum N, Allalunis-Turner J (2009) Expression and hypoxic up-regulation of neuroglobin in human glioblastoma cells. *Mol Oncol* 3(1):45–53
154. Xie LK, Yang SH (2016) Brain globins in physiology and pathology. *Med Gas Res* 6(3):154–163
155. Pesce A, Dewilde S, Nardini M, Moens L, Ascenzi P, Hankeln T, Burmester T, Bolognesi M (2003) Human brain neuroglobin structure reveals a distinct mode of controlling oxygen affinity. *Structure* 11(9):1087–1095
156. Amri F, Ghouili I, Amri M, Carrier A, Masmoudi-Kouki O (2017) Neuroglobin protects astroglial cells from hydrogen peroxide-induced oxidative stress and apoptotic cell death. *J Neurochem* 140(1):151–169
157. Brittain T (2012) The anti-apoptotic role of neuroglobin. *Cells* 1(4):1133–1155
158. Fago A, Mathews AJ, Brittain T (2008) A role for neuroglobin: resetting the trigger level for apoptosis in neuronal and retinal cells. *IUBMB Life* 60(6):398–401
159. Sugitani K, Koriyama Y, Sera M, Arai K, Ogai K, Wakasugi K (2017) A novel function of neuroglobin for neuroregeneration in mice after optic nerve injury. *Biochem Biophys Res Commun* 493(3):1254–1259
160. Haines B, Demaria M, Mao X, Xie L, Campisi J, Jin K, Greenberg DA (2012) Hypoxia-inducible factor-1 and neuroglobin expression. *Neurosci Lett* 514(2):137–140
161. Liu N, Yu Z, Li Y, Yuan J, Zhang J, Xiang S, Wang X (2013) Transcriptional regulation of mouse neuroglobin gene by cyclic AMP responsive element binding protein (CREB) in N2a cells. *Neurosci Lett* 534:333–337

162. Liu N, Yu Z, Xiang S, Zhao S, Tjamlund-Wolf A, Xing C, Zhang J, Wang X (2012) Transcriptional regulation mechanisms of hypoxia-induced neuroglobin gene expression. *Biochem J* 443(1):153–164
163. Burmester T, Hankeln T (2009) What is the function of neuroglobin? *J Exp Biol* 212(Pt 10):1423–1428
164. De Marinis E, Acaz-Fonseca E, Arevalo MA, Ascenzi P, Fiocchetti M, Marino M, Garcia-Segura LM (2013) 17beta-Oestradiol anti-inflammatory effects in primary astrocytes require oestrogen receptor beta-mediated neuroglobin up-regulation. *J Neuroendocrinol* 25(3):260–270
165. Kakar S, Hoffman FG, Storz JF, Fabian M, Hargrove MS (2010) Structure and reactivity of hexacoordinate hemoglobins. *Biophys Chem* 152(1–3):1–14
166. Trent JT 3rd, Watts RA, Hargrove MS (2001) Human neuroglobin, a hexacoordinate hemoglobin that reversibly binds oxygen. *J Biol Chem* 276(32):30106–30110
167. Taylor JM, Kelley B, Gregory EJ, Berman NE (2014) Neuroglobin overexpression improves sensorimotor outcomes in a mouse model of traumatic brain injury. *Neurosci Lett* 577:125–129
168. Van Leuven W, Van Dam D, Moens L, De Deyn PP, Dewilde S (2013) A behavioural study of neuroglobin-overexpressing mice under normoxic and hypoxic conditions. *Biochim Biophys Acta* 1834(9):1764–1771
169. Yu Z, Poppe JL, Wang X (2013) Mitochondrial mechanisms of neuroglobin's neuroprotection. *Oxidative Med Cell Longev* 2013:756989
170. Yu Z, Xu J, Liu N, Wang Y, Li X, Pallast S, van Leyen K, Wang X (2012) Mitochondrial distribution of neuroglobin and its response to oxygen-glucose deprivation in primary-cultured mouse cortical neurons. *Neuroscience* 218:235–242
171. Ye SQ, Zhou XY, Lai XJ, Zheng L, Chen XQ (2009) Silencing neuroglobin enhances neuronal vulnerability to oxidative injury by down-regulating 14-3-3gamma. *Acta Pharmacol Sin* 30(7):913–918
172. Antao ST, Duong TT, Aran R, Witting PK (2010) Neuroglobin overexpression in cultured human neuronal cells protects against hydrogen peroxide insult via activating phosphoinositide-3 kinase and opening the mitochondrial K (ATP) channel. *Antioxid Redox Signal* 13(6):769–781
173. Garofalo T, Ferri A, Sorice M, Azmoon P, Grasso M, Mattei V, Capozzi A, Manganelli V et al (2018) Neuroglobin overexpression plays a pivotal role in neuroprotection through mitochondrial raft-like microdomains in neuroblastoma SK-N-BE2 cells. *Mol Cell Neurosci* 88:167–176
174. Jin K, Mao X, Xie L, Greenberg DA (2012) Interactions between vascular endothelial growth factor and neuroglobin. *Neurosci Lett* 519(1):47–50
175. Nakatani K, Okuyama H, Shimahara Y, Saeki S, Kim DH, Nakajima Y, Seki S, Kawada N et al (2004) Cytoglobin/STAP, its unique localization in splanchnic fibroblast-like cells and function in organ fibrogenesis. *Lab Invest* 84(1):91–101